Compare QMCO & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | IMRN |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 12.0M |
| IPO Year | N/A | N/A |
| Metric | QMCO | IMRN |
|---|---|---|
| Price | $7.19 | $0.91 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | 481.4K | ★ 1.3M |
| Earning Date | 02-11-2026 | 08-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $256,949,000.00 | $4,777,422.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.63 |
| 52 Week Low | $6.51 | $0.91 |
| 52 Week High | $90.64 | $2.48 |
| Indicator | QMCO | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 23.77 |
| Support Level | $7.07 | $0.91 |
| Resistance Level | $7.88 | $0.97 |
| Average True Range (ATR) | 0.66 | 0.06 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 7.00 | 0.00 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.